Tenascin and fibronectin expression in carcinoma ex pleomorphic adenoma.
This study was conducted to analyze the participation of tenascin and fibronectin, components of the extracellular matrix, in different types of carcinoma ex pleomorphic adenoma (CXPA). Seventeen cases of CXPA, classified according to the presence of epithelial and myoepithelial cells and the degree of invasion-intracapsular, minimally, and frankly invasive carcinoma-were immunohistochemically labeled for tenascin and fibronectin. Normal salivary gland included in the specimens showed tenascin only around the excretory duct, and fibronectin slightly expressed all over the stroma of the gland. In reminiscent pleomorphic adenoma, tenascin and fibronectin were observed around tubular structures and in the stroma. Both tenascin and fibronectin were expressed in all the CXPA studied. In areas of in situ carcinoma of the intracapsular type, the expression of these extracellular matrix proteins was enhanced compared with areas of residual pleomorphic adenoma. In intracapsular and minimally invasive types of CXPA, some areas of the tumor border presented tenascin and no fibronectin, pattern that may represent the real invasive front. In frankly invasive CXPA type with only epithelial component, fibronectin was strongly observed in a fibrillar network pattern, and tenascin was only focal. In frankly invasive type with myoepithelial component, tenascin staining was very strong and diffuse. This study showed different patterns of expression of tenascin and fibronectin along the process of tumorigenesis and tumor progression in CXPA, a fact that might play a role in invasion properties of these tumors.
Araújo
Vera Cavalcanti de
VC
Department of Oral Pathology, São Leopoldo Mandic Dental Research Center, University of São Paulo, Brazil. veraa@slmandic.com.br
Furuse
Cristiane
C
Cury
Patricia Ramos
PR
Altemani
Albina
A
Alves
Venâncio Avancini Ferreira
VA
de Araújo
Ney Soares
NS
D008949:Adenoma, Pleomorphic / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005353:Fibronectins / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012468:Salivary Gland Neoplasms / Q000378:metabolism*; D019063:Tenascin / Q000032:analysis / Q000378:metabolism*
D005353:Fibronectins; D019063:Tenascin